Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International — Technical Presentation (May 2008)

20 slides from Valeant Pharmaceuticals International's technical presentation, May 13, 2008

  1. Slide 1: RESTORE 2 Summary Results

    RESTORE 2 Summary Results May 13, 2008

  2. Slide 2: Retigabine: first-in-class neuronal potassium channel opener

    Retigabine A first-in-class neuronal potassium channel opener A novel mechanism of action A promising approach to treatment of epilepsy and other CNS diseases

  3. Slide 3: Retigabine Clinical Program

    Retigabine Clinical Program Positive, published* results from Study 205, the retigabine Phase IIb trial in epilepsy Tested 600, 900, and 1200 mg doses Positive results from RESTORE 1 Tested 1200 mg dose Positive results from RESTORE 2 available now Tested 600 mg and 900 mg doses Anticipate submittin

  4. Slide 4: Trials: Overview

    RESTORE Trials: Overview Pair of Phase III studies with similar design Randomized, double-blind, placebo-controlled Adult epilepsy patients with refractory partial-onset seizures on a stable regimen of 1 - 3 background anti-epileptic drugs (AEDs) Primary endpoints and study design appropriate to mee

  5. Slide 5: Primary Efficacy Endpoints

    Primary Efficacy Endpoints FDA Submission Median reduction in total partial-seizure frequency per 28 days from baseline to the end of the double-blind period EMEA* Submission Proportion of responders (>50% reduction in seizure frequency per 28 days comparing maintenance period to baseline) *EMEA = E

  6. Slide 6: Study Design

    RESTORE 2 - Study Design 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Baseline Phase (8 weeks) Titration Phase (4 weeks) Maintenance Phase (12 weeks) 16-Week Double-Blind Phase Retigabine 900 mg/day Randomization Start Retigabine 300 mg/day (increase by 150 mg/day every week) Placebo Transit

  7. Slide 7: Patient Disposition

    Patient Disposition *Safety / ITT = all subjects who took at least 1 dose of study medication Data on file. Valeant Pharmaceuticals International.

  8. Slide 8: Summary Patient Characteristics

    Summary Patient Characteristics CGI= Clinician's Global Impression ITT population Data on file. Valeant Pharmaceuticals International.

  9. Slide 9: Primary Endpoint Results: FDA Endpoint

    Primary Endpoint Results: FDA Endpoint Median reduction in 28-day total partial seizure frequency ** * ** * *p < 0.01 **p < 0.001 Median Reduction (%) ** ** ** * * * FDA endpoint ITT population Data on file. Valeant Pharmaceuticals International. 179 181 178 164 158 149 179 181 178

  10. Slide 10: Primary Endpoint Results: CHMP Endpoint for EMEA submission

    Primary Endpoint Results: CHMP† Endpoint for EMEA submission * ** ** * *p ^ 0.01 **p < 0.001 Responders (%) Responder Rate: ^50% decrease in 28-day total partial seizure frequency ** ** ** * * * CHMP endpoint †CHMP = European Union Committee for Human Medicinal Products ITT population Data on file.

  11. Slide 11: Most Common Treatment-Emergent Adverse Events On Retigabine

    Most Common (^ 10%) Treatment-Emergent Adverse Events On Retigabine Data on file. Valeant Pharmaceuticals International. Safety Population

  12. Slide 12: Program Results

    RESTORE PROGRAM RESULTS WYALEANT

  13. Slide 13: Program: FDA endpoint

    RESTORE Program: FDA endpoint Median Reduction (%) Data on file. Valeant Pharmaceuticals International. Median reduction in 28-day total partial seizure frequency ITT population Double-blind phase *p ^ 0.01 **p < 0.001 ** ** * 151 179 181 178 150

  14. Slide 14: Program: EMEA endpoint

    RESTORE Program: EMEA endpoint Responders (%) Data on file. Valeant Pharmaceuticals International. Responder Rate: ^50% decrease in 28-day total partial seizure frequency ITT population Maintenance phase *p ^ 0.01 **p < 0.001 ** ** * 138 164 158 149 119

  15. Slide 15: Program: Per Protocol Population Results

    RESTORE Program: Per Protocol Population Results Responder Rate: ^50% decrease in 28-day total partial seizure frequency Responders (%) Per protocol = Completers without major protocol violation * * 122 149 130 117 89 *p < 0.001 * Data on file. Valeant Pharmaceuticals International.

  16. Slide 16: Most Common Treatment-Emergent Adverse Events On Retigabine

    Most Common (^ 10%) Treatment-Emergent Adverse Events On Retigabine

  17. Slide 17: Safety experience

    Safety experience Total subjects exposed: 1750+ Total epilepsy patients exposed: 1350+ 700+ patients for a minimum of 6 months 350+ patients for a minimum of 12 months Some subjects will have taken RTG for more than 6 years

  18. Slide 18: Program - Conclusions

    RESTORE Program - Conclusions Met primary endpoints for FDA and CHMP Statistically superior to placebo (p<0.01) at all doses Clear dose response established Short titration to an effective dose Well-tolerated Adverse events generally dose-related Extensive safety experience Validates novel mechanism

  19. Slide 19: Retigabine Program - Next Steps

    Retigabine Program - Next Steps Submission to US and EU regulatory agencies in 2008 PHN (neuropathic pain) study ongoing Data anticipated in 2009 Modified release program on track Pediatric studies to start in 2009 Follow-on program, VRX698, expected to enter clinic by end of 2008

  20. Slide 20: Retigabine: Commercial Implications

    Retigabine: Commercial Implications Commercial opportunity on par with leading 2nd generation AEDs Partnering process well underway Launch preparations beginning in earnest Evaluating opportunities in epilepsy and other disease areas

Valeant Pharmaceuticals International — Technical Presentation (May 2008) on 6ix